The primary objectives of this multicenter, open-label phase I/II Trial includes a dose-escalation part to evaluate safety, tolerability and to determine the recommended Phase II dose (RP2D) of MORAb-202, and a an expansion part to evaluate the objective response rate (ORR) in each of the...
Although the phase III trial did not meet its primary statistical endpoint of progression-free survival, the addition of farletuzumab to standard chemotherapy for patients with relapsed platinum-sensitive ovarian cancer did not increase toxicity [13]. As a result of its strong safety profile in ...